Baird Financial Group Inc. Sells 6,141 Shares of BioNTech SE Sponsored ADR $BNTX

Baird Financial Group Inc. lessened its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 33.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,448 shares of the company's stock after selling 6,141 shares during the period. Baird Financial Group Inc.'s holdings in BioNTech were worth $1,134,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. Deutsche Bank AG boosted its stake in shares of BioNTech by 2.3% during the fourth quarter. Deutsche Bank AG now owns 304,500 shares of the company's stock valued at $34,698,000 after purchasing an additional 6,749 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of BioNTech during the fourth quarter valued at about $570,000. Integral Health Asset Management LLC boosted its stake in shares of BioNTech by 100.0% during the fourth quarter. Integral Health Asset Management LLC now owns 100,000 shares of the company's stock valued at $11,395,000 after purchasing an additional 50,000 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of BioNTech during the fourth quarter valued at about $1,014,000. Finally, Raiffeisen Bank International AG acquired a new stake in shares of BioNTech during the fourth quarter valued at about $1,126,000. Institutional investors own 15.52% of the company's stock.

BioNTech Trading Down 7.3%

BNTX traded down $7.57 during trading on Friday, hitting $96.74. The company's stock had a trading volume of 5,152,296 shares, compared to its average volume of 874,805. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $131.49. The stock's fifty day moving average price is $108.79 and its 200-day moving average price is $103.98. The firm has a market capitalization of $23.26 billion, a P/E ratio of -60.46 and a beta of 1.39.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The firm had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same period in the previous year, the company earned ($3.36) earnings per share. BioNTech's revenue for the quarter was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. Analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Leerink Partners set a $112.00 price objective on BioNTech in a research note on Monday, June 2nd. The Goldman Sachs Group assumed coverage on BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective on the stock. Truist Financial reaffirmed a "buy" rating and issued a $155.00 price objective (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $136.00 price objective on shares of BioNTech in a research note on Monday, September 8th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.